{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:07:16Z","timestamp":1791274036822,"version":"4.1.0"},"reference-count":65,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2019,2,28]]},"DOI":"10.2217\/fon-2018-0607","type":"journal-article","created":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T14:33:22Z","timestamp":1539873202000},"page":"349-358","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":40,"title":["Nivolumab and Ipilimumab: Immunotherapy for Treatment of Malignant Melanoma"],"prefix":"10.1080","volume":"15","author":[{"given":"Nicole A","family":"Carreau","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, New York University Langone Medical Center, New York, NY 10016,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C","family":"Pavlick","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, New York University Langone Medical Center, New York, NY 10016,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,10,18]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(72)90087-4"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197103)27:3<744::AID-CNCR2820270335>3.0.CO;2-O"},{"issue":"1","key":"e_1_3_3_5_1","first-page":"21","article-title":"Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview","volume":"19","author":"Serrone L","year":"2000","unstructured":"Serrone L , ZeuliM, SegaFM, CognettiF. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J. Exp. Clin. Cancer Res.19(1), 21\u201334 (2000).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00086"},{"issue":"6","key":"e_1_3_3_7_1","first-page":"488","article-title":"Treatment of metastatic melanoma: an overview","volume":"23","author":"Bhatia S","year":"2009","unstructured":"Bhatia S , TykodiSS, ThompsonJA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park)23(6), 488\u2013496 (2009).","journal-title":"Oncology (Williston Park)"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1382472"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.12.002"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30139-6"},{"key":"e_1_3_3_16_1","article-title":"Unresectable and metastatic melanoma of the skin: literature review of clinical trials and efficacy end points since 2000","author":"Jin S","year":"2018","unstructured":"Jin S , Mishra-KalyaniPS, SridharaR. Unresectable and metastatic melanoma of the skin: literature review of clinical trials and efficacy end points since 2000. Ther. Innov. Regul. Sci.2168479018769286 (2018) (Epub ahead of print).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"e_1_3_3_17_1","article-title":"Systemic treatments for metastatic cutaneous melanoma","volume":"2","author":"Pasquali S","year":"2018","unstructured":"Pasquali S , HadjinicolaouAV, Chiarion SileniV, RossiCR, MocellinS. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst. Rev.2, CD011123 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_3_18_1","unstructured":"American Academy of Dermatology . Types of skin cancer (2018). www.aad.org\/public\/spot-skin-cancer\/learn-about-skin-cancer\/types-of-skin-cancer."},{"key":"e_1_3_3_19_1","unstructured":"National Cancer Institute: SEER program . Cancer stat facts: melanoma of the skin (2018). https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html."},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2017.10.008"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20184779"},{"key":"e_1_3_3_23_1","unstructured":"Yervoy\u2122 (ipilimumab) injection prescribing information. Bristol-Myers Squibb Princeton NJ USA (2018). https:\/\/packageinserts.bms.com\/pi\/pi_."},{"key":"e_1_3_3_24_1","unstructured":"Opdivo\u2122 (nivolumab) injection prescribing information. Bristol-Myers Squibb Princeton NJ USA (2018). https:\/\/packageinserts.bms.com\/pi\/pi_"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2051"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.8954"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.09.015"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12323"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750"},{"issue":"9","key":"e_1_3_3_31_1","first-page":"503","article-title":"Ipilimumab (Yervoy\u2122) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use","volume":"37","author":"Fellner C","year":"2012","unstructured":"Fellner C . Ipilimumab (Yervoy\u2122) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T37(9), 503\u2013530 (2012).","journal-title":"P T"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12143"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032414-112049"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2762"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/85330"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2014.980235"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0244"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0040"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.3.1257"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2736"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_3_3_43_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9507","article-title":"Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the Phase II study checkmate 204","volume":"35","author":"Tawbi H","year":"2017","unstructured":"Tawbi H , ForsythP, AlgaziA, HamidO, HodiF, MoschosS. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the Phase II study checkmate 204. J. Clin. Oncol.35(Suppl.), Abstract 9507 (2017).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611299"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.2177\/jsci.40.83"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.025"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0047"},{"issue":"3","key":"e_1_3_3_49_1","first-page":"88","article-title":"Managing the adverse effects related to immune checkpoint inhibitors","volume":"65","author":"Kuo H-H","year":"2018","unstructured":"Kuo H-H , ChenW-W. Managing the adverse effects related to immune checkpoint inhibitors. Hu Li Za Zhi65(3), 88\u201395 (2018).","journal-title":"Hu Li Za Zhi"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8890-z"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170407125017"},{"key":"e_1_3_3_52_1","first-page":"296","article-title":"Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal","volume":"179","author":"Wan MT","year":"2018","unstructured":"Wan MT , MingME. Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal. Br. J. Dermatol.179, 296\u2013300 (2018).","journal-title":"Br. J. Dermatol."},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq013"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1595"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.9500"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1024"},{"key":"e_1_3_3_57_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.10009","article-title":"Efficacy and safety of checkpoint blockage for treatment of advanced melanoma in patients age 80 and older (80+)","volume":"34","author":"Friedman C","year":"2016","unstructured":"Friedman C , HorvatT, MinehartJet al. Efficacy and safety of checkpoint blockage for treatment of advanced melanoma in patients age 80 and older (80+). J. Clin. Oncol.34(Suppl.), Abstract 10009 (2016).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx642"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30428-X"},{"key":"e_1_3_3_60_1","unstructured":"ClinicalTrials.gov : NCT03068455. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03068455"},{"issue":"13","key":"e_1_3_3_61_1","article-title":"Abstract SY09-01: next-generation anti-CTLA-4 antibodies. Proceedings of the American Association for Cancer Research Annual Meeting 2017, Washington, DC, Philadelphia, USA","volume":"77","author":"Korman AJ","year":"2017","unstructured":"Korman AJ , EngelhardtJ, LoffredoJet al. Abstract SY09-01: next-generation anti-CTLA-4 antibodies. Proceedings of the American Association for Cancer Research Annual Meeting 2017, Washington, DC, Philadelphia, USA. Cancer Res.77(13 Suppl.), Abstract SY09-01 (2017).","journal-title":"Cancer Res."},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.9520"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0314-0"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/897348"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2018.02.007"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3530148"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000223"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2018-0607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:54Z","timestamp":1719125154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2018-0607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,18]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,2,28]]}},"alternative-id":["10.2217\/fon-2018-0607"],"URL":"https:\/\/doi.org\/10.2217\/fon-2018-0607","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}